Clinical trials: Minimal Residual Disease
Acute Lymphoblastic Leukemia
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
A study on the effectiveness and safety of haploidentical hematopoietic stem cell transplantation in patients with MRD positive CD19+ ALL treated with conditioning regimens containing Blinatumomab
- Trial name
- NCT06125106
- Testing
- Blinatumomab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang University
Lymphoma
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the…
- Trial name
- NCT05676450
- Testing
- cell-free DNA
- Where
- 2 sites in United States
- Volunteers
- 517 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.
- Trial name
- NCT07264010
- Testing
- Sorafenib (SORA), Venetoclax (VEN)
- Volunteers
- 87 people
- Sponsor
- Nanfang Hospital, Southern Medical University
AML, Adult
MRD-positive AML Clinical Study
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the…
- Trial name
- NCT07131059
- Testing
- Ivosidenib, Gilteritinib, Venetoclax
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China